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Introduction: Prevalence estimates of ankylosing spondylitis vary considerably, and there are few nationwide
estimates. The present study aimed to describe the national prevalence of clinically diagnosed ankylosing
spondylitis in Sweden, stratified according to age, sex, geographical, and socio-economic factors, and according to
subgroups with ankylosing spondylitis-related clinical manifestations and pharmacological treatment.
Methods: All individuals diagnosed with ankylosing spondylitis according to the World Health Organization
International Classification of Disease codes, between 1967 and 2009, were identified from the National Patient
Register. Data regarding disease manifestations, patient demographics, level of education, pharmacological
treatment, and geographical region were retrieved from the National Patient Register and other national registers.
Results: A total of 11,030 cases with an ankylosing spondylitis diagnosis (alive, living in Sweden, and 16 to 64 years
old in December 2009) were identified in the National Patient Register, giving a point prevalence of 0.18% in 2009.
The prevalence was higher in northern Sweden, and lower in those with a higher level of education. Men had a
higher prevalence of ankylosing spondylitis (0.23% versus 0.14%, P < 0.001), a higher frequency of anterior uveitis
(25.5% versus 20.0%, P < 0.001) and were more likely to receive tumor necrosis factor inhibitors than women (15.6%
versus 11.8% in 2009, P < 0.001). Women were more likely than men to have peripheral arthritis (21.7% versus
15.3%, P < 0.001), psoriasis (8.0% versus 6.9%, P = 0.03), and treatment with oral corticosteroids (14.0% versus 10.4%
in 2009, P < 0.001).
Conclusion: This nationwide, register-based study demonstrated a prevalence of clinically diagnosed ankylosing
spondylitis of 0.18%. It revealed phenotypical and treatment differences between the sexes, as well as geographical
and socio-economic differences in disease prevalence.Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disorder primarily involving the sacroiliac joints and spine.
It is associated with both articular and extra-articular clin-
ical manifestations, including peripheral arthritis, enthesi-
tis, anterior uveitis, psoriasis, and inflammatory bowel
disease. The first symptoms usually occur before the age
of 30 and seldom occur after the age of 45 [1]. The
chronic and often progressive nature of the disease af-
fects individuals for most of their working lives, limiting* Correspondence: sofiaexar@hotmail.com
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stated.physical function, the ability to work, and perceived
quality of life [2,3]. Pharmacological treatments include
non-steroidal anti-inflammatory drugs (NSAIDs), oral
glucocorticoids, synthetic disease modifying anti-rheumatic
drugs (sDMARDs), and tumor necrosis factor inhibitors
(TNFi) [4].
Compared with rheumatoid arthritis (RA), few studies
have examined the prevalence of AS. The prevalence in
Europe, North America, and China is estimated at 0.03
to 1.8% [5-17]; however, estimates are lower in Japan [18]
and higher in populations with a high frequency of the
major risk gene, HLA-B27 [19].
The highly varying estimates in the West may reflect
differences in study methodology. Studies used differental. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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small population surveys [12,11,5,7,6,9], general epi-
demiological surveys [14], blood donor registers [16],
and regional patient registers [15]. The population sur-
veys performed to date also used different screening
methods, including telephone interviews [5], postal sur-
veys [6,9], and home-based interviews [7].
Accurate and contemporary prevalence estimates, in-
cluding the frequency of AS-related clinical manifestations
and pharmacological treatments, as well as socio-economic
and geographical variations, are important for healthcare
planning, and they may provide clues to possible risk fac-
tors for the disease. Furthermore, little is known about dif-
ferences in disease manifestations and pharmacological
treatments between the sexes at the population level. One
approach to obtaining such information is to use national
healthcare registers, a method that has only been used on a
regional level for AS [15], but was successfully used on a
national level for RA [20]. This approach is supported by
the high validity of the Swedish National Patient Register
(NPR) in general [21], and by our recent assessment of the
validity of the International Classification of Disease (ICD)
codes [22] for AS in the Swedish NPR; the ICD codes
showed high validity with regard to fulfilling the estab-
lished classification criteria for both AS and spondyloar-
thritis (SpA) [23,24].
The primary aim of the present study was to assess
the total national point prevalence of clinically diag-
nosed AS in Sweden in December 2009, and to stratify
the prevalence according to age, sex, geographical and
socio-economic factors. We also stratified the preva-
lence according to AS-related clinical manifestations
and pharmacological treatments. The secondary aim
was to compare disease manifestations and pharmaco-
logical treatments between the sexes.
Methods
Setting
The data used in this nationwide, population-based
study were obtained from the Swedish national health-
care registers.
Healthcare provision in Sweden is largely funded by
the taxpayer and is independent of individual financial
or insurance considerations. There is an upper limit to
an individual’s yearly costs for medical consultations and
prescription medications. Patients with an inflammatory
rheumatic disease such as AS are usually diagnosed at
public or (less commonly) private rheumatology clinics.
Such cases are rarely definitively diagnosed in a primary
care setting [25].
Ethical approval for the study was granted by the Re-
gional Ethics Committee, Karolinska Institute, Stockholm,
Sweden. Patient consent was waived, as data were derived
either from administrative registers that do not requireinformed consent or quality registers where the consent is
already given at the time point of first registration.
Data sources
The NPR comprises the Inpatient Register (IPR) and the
Outpatient Register (OPR). The IPR was launched in
1964, and complete national coverage (almost 100%) was
achieved in 1987. The IPR contains data (medical and
administrative) derived from all patients discharged from
hospitals in Sweden [21]. The OPR for public specialized
care was started in 2001. The national coverage of the
OPR is lower (approximately 73% in 2008 and 87% in
2011) [26,27] than that of the IPR, mainly due to missing
data from private caregivers. Visits to primary care facil-
ities are not covered by the NPR. Diagnoses are regis-
tered using the Swedish version of the ICD codes [22].
The present study used the NPR to identify AS cases
and AS-related clinical manifestations between 1967 and
2009. An additional table shows the ICD codes used in
the present study (Additional file 1: Table S1).
The Swedish Prescribed Drug Register [28] contains in-
formation about all prescribed drugs dispensed by Swedish
pharmacies since July 2005. This register was used to de-
termine the exposure of patients with a registered diagno-
sis of AS to NSAIDs, oral corticosteroids, and sDMARDs
during 2009. Exposure to TNFi during 2009 was based on
data retrieved from the Swedish Biologics Register (the
Anti-Rheumatic Therapy in Sweden Register; ARTIS) [29],
which was initiated in 1999 and includes over 85% of
subcutaneous and intravenous TNFi prescribed for AS
[30]. An individual was considered to be “exposed” in
2009 if they had at least one prescription dispensed or,
in the case of TNFi, were listed in ARTIS as receiving
medication during 2009.
Demographic data were obtained from Statistics Sweden
[31], which holds data on immigration, emigration, and
residency, as well as data on socio-economic factors (for
example, marital status and level of formal education) for
all those residing in Sweden.
Vital status on 31 December 2009 was determined via
the cause-of-death register [32], which provides informa-
tion on the date and cause(s) of death for all residents
since 1961.
All data in the Swedish national healthcare registers
are accessed via a personal identification number, which
provides the link between all of the registers used in the
present analyses [33].
Definition of ankylosing spondylitis
All individuals with an ICD diagnosis registration of AS
between 1967 and 2009 were identified from the NPR
(Figure 1). The base case definition required at least one
AS diagnosis to be registered in the NPR (IPR 1967 to
2009 and/or OPR 2001 to 2009) by any department at a
Figure 1 Flow chart showing the process of identifying patients with a registered ankylosing spondylitis (AS) diagnosis according to the World
Health Organization International Classification of Disease codes in the National Patient Register between 1967 and 2009 according to the base
case and strict case definition.
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at least one AS diagnosis to be registered by a department
of rheumatology or internal medicine (Figure 1), a def-
inition that we have previously found to have a high
validity [23].
The case definitions used herein included individuals
who had received their AS diagnosis for the first time
before the age of 16, and also individuals diagnosed with
juvenile idiopathic arthritis who had a subsequent diag-
nosis of AS. This is because these conditions were con-
sidered to be part of the same adult AS phenotype.
Results were obtained for individuals aged 16 to 64
years in 2009. The upper age limit was chosen to ensure
a high case identification and at the same time minimize
the flawing of the results which could be possibly caused
by the inclusion of older individuals. Although >95% of
patients with AS experience disease onset before the age
of 45, there is a considerable delay (8 to 15 years) in
obtaining a definitive diagnosis from a specialist in
Sweden [23,15], meaning that a high age limit was re-
quired in order to maximize the number of cases enrolled.
Moreover, since the major source used to identify AS
cases, the OPR, did not start until 2001, the ability toaccurately identify AS cases in older age groups with earl-
ier disease onset, and who were exclusively diagnosed in a
specialized outpatient care setting, was limited. Estimates
of disease prevalence in older age groups may also be
flawed due to the high mortality among AS patients [34].
Also, it may be that few AS diagnoses are made in older
age groups due to either the limited impact of the disease
on older people [35] or the influence of other major age-
related co-morbidities on diagnosis registration patterns.
Geographical variations and level of formal education
There are six healthcare regions in Sweden: one northern,
one southern, and four in between (the southeastern and
western regions, and the Uppsala-Örebro and Stockholm
regions). These regions were used to calculate the regional
prevalence of clinically diagnosed AS and are presented in
Additional file 2: Figure S1.
The level of formal education was classified into three
categories (≤9 years, 10 to 12 years, and >12 years of
schooling). The prevalence of clinically diagnosed AS in
relation to the level of education is presented for those
aged ≥30 years, the age by which the majority of the
population is expected to have completed their studies.
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The total point prevalence of clinically diagnosed AS was
estimated on 31 December 2009 according to both the base
case and strict case definitions, and after stratification
according to sex and age. Despite the cumulative ascertain-
ment of AS cases, the term “point prevalence” is used. Con-
sidering that AS is a chronic disease, individuals with a
previous registered AS diagnosis, alive and living in Sweden
in 2009, are assumed having an AS diagnosis on 31 December
2009 as well. The point prevalence of AS was thus calcu-
lated by taking the number of AS individuals according to
each definition and dividing it by the Swedish population
on 31 December 2009 with similar age. Furthermore, the
prevalence was estimated for subgroups based on AS-related
clinical manifestations and pharmacological treatment, by
taking the number of AS individuals (according to the base
case definition) having dispensed prescriptions for each
pharmacological treatment during any part of 2009, or
those with a registered diagnosis of AS-related disease
manifestations between 1967 and 2009, and dividing it by
the Swedish population on 31 December 2009 with similar
age. Crude and age-/sex-standardized point prevalence esti-
mates according to healthcare region and level of formal
education were also calculated. Standardization was per-
formed to the Swedish population aged 16 to 64 years in
2009. For comparisons between the sexes, the Chi-squared
test was used for categorical variables, and the Student’s
t-test was used for normally distributed continuous vari-
ables. P-values <0.05 were considered statistically signifi-
cant. For comparisons between geographical location and
socio-economic factors, statistical significance was based on
the absence of overlap between the estimated 95% confi-
dence interval (CI). Logistic regression models adjusted for
age and AS-related clinical manifestations (psoriasis, in-
flammatory bowel disease, anterior uveitis, and peripheral
arthritis) were used to examine sex-related differences in
treatment patterns. All analyses were performed using IBM
SPSS Statistics for Windows, Version 20.0. Armonk, NY:
IBM Corp and Microsoft Excel 2010, Microsoft Corporation,
One Microsoft Way, Redmond, WA, USA.
Results
On 31 December 2009, the population of Sweden was
about 9.3 million, of which 64% (5,982,237) were aged 16 to
64 years (the denominator in this study). Males accounted
for 50.8%.
We identified 20,044 AS cases registered in the NPR
between 1967 and 2009 (Figure 1). Of those, 11,030 were
aged between 16 and 64 years, alive, and living in Sweden
on 31 December 2009. Of these 11,030 individuals, 76%
(n = 8,379) were registered in the OPR, 48.5% (n = 5,350) in
the IPR, and 24.5% (n = 2,699) in both. Of those fulfilling
the base case definition of AS, 7,041 (63.8%) were male. The
mean age in 2009 was 48.3 years (standard deviation (SD)11.3) and the mean age at the time of first AS diagnosis
registration in the NPR was 38.6 years (SD 11.4) (Table 1).
Of those fulfilling the base case definition, 77.4% (n = 8,538)
also fulfilled the strict case definition (Figure 1).
Prevalence of clinically diagnosed ankylosing spondylitis,
pharmacological treatment, and disease manifestations
The total point prevalence of clinically diagnosed AS (16
to 64 years old) on 31 December 2009, according to both
base case and strict case definitions, was 0.18% (11,030/
5,982,237) and 0.14% (8,538/5,982,237), respectively. Of
the AS cases identified between 1967 and 2009 according
to the base case definition, 68.4% had a registered visit in
the NPR during the period 2005 to 2009 (7,550/11,030).
The prevalence of AS according to the base case definition
having any dispensed prescription for NSAIDs during 2009
was 0.10%, while the prevalence for those with any dis-
pensed prescription for sDMARDs or TNFi during 2009,
or those registered with AS-related clinical manifestations
between 1967 and 2009, was considerably lower (Figure 2).
There were differences between the sexes with regard to
pharmacological treatments received during 2009. Women
were more often treated with oral corticosteroids than
men (P < 0.001), whereas men were more often treated
with TNFi (P < 0.001) (Table 1). There were also differences
between the sexes regarding some AS-related clinical man-
ifestations. Anterior uveitis was more common in men
(P < 0.001), and peripheral arthritis and psoriasis were
more common in women (P < 0.001 and P = 0.03, respect-
ively) (Table 1). The sex-related differences with regard to
treatment with TNFi (odds ratio = 1.48; 95% CI, 1.32 to
1.67; P < 0.001) and oral corticosteroids (odds ratio = 1.35;
95% CI, 1.20 to 1.52; P < 0.001) remained significant after
adjustment for age and AS-related clinical manifestations
(psoriasis, inflammatory bowel disease, anterior uveitis,
and peripheral arthritis) in logistic regression models.
Data regarding demographics, disease manifestations,
pharmacological treatment, and sex-related differences
were similar regardless of whether the base case or strict
case definitions of AS were used, as shown in detail in
Additional file 3: Table S2.
The prevalence of clinically diagnosed AS increased
linearly with age up to the age of 55 years, and then
reached a plateau. For all age groups combined, the preva-
lence of AS was higher in men than in women (0.23% ver-
sus 0.14%; P < 0.001). The male-to-female ratio was highest
after the age of 50; however, it was lower for younger age
groups (Figure 3). The same pattern was observed for the
prevalence of AS according to the strict case definition
after age and sex stratification (Additional file 4: Figure S2).
Geographical location
Estimates according to healthcare region revealed that the
age-/sex-standardized prevalence of clinically diagnosed
Table 1 Demographics, pharmacological treatment, and ankylosing spondylitis (AS)-related clinical manifestations in
patients with an ankylosing spondylitis diagnosis in the National Patient Register (1967 to 2009) according to the
base case and strict case definitions
Base case definition Strict case definition
Men Women Total Total
(N = 7,041) (N = 3,989) (N = 11,030) (N = 8,538)
Demographics Mean (SD) P-value Mean (SD) Mean (SD)
Age at diagnosis registration 38.6 (11.4) 38.6 (11.3) 0.907 38.6 (11.4) 39.1 (11.0)
Age on 31 December 2009 48.6 (11.2) 47.6 (11.5) <0.001 48.3 (11.3) 48.5 (10.9)
Pharmacological treatment during 2009† N (% of total) P-value††† N (% of total)
NSAIDs 3,724 (52.9) 2,164 (54.2) 0.169 5,888 (53.4) 4,736 (55.5)
Oral corticosteroids 734 (10.4) 557 (14.0) <0.001 1,291 (11.7) 1,078 (12.6)
sDMARDs 1,406 (20.0) 841 (21.1) 0.163 2,247 (20.4) 1,937 (22.7)
TNFi 1,100 (15.6) 471 (11.8) <0.001 1,571 (14.2) 1,442 (16.9)
Any pharmacological treatment 4,634 (65.8) 2,653 (66.5) 0.460 7,287 (66.1) 5,974 (70.0)
AS-related clinical manifestations (1967–2009)†† N (% of total) P-value N (% of total)
Anterior uveitis 1,797 (25.5) 797 (20.0) <0.001 2,594 (23.5) 2,109 (24.7)
Psoriasis 486 (6.9) 320 (8.0) 0.030 806 (7.3) 669 (7.8)
IBD 571 (8.1) 343 (8.6) 0.371 914 (8.3) 746 (8.7)
Peripheral arthritis 1,079 (15.3) 864 (21.7) <0.001 1,943 (17.6) 1,568 (18.4)
Hip arthroplasty 527 (7.5) 319 (8.0) 0.331 846 (7.7) 658 (7.7)
Synthetic disease modifying anti-rheumatic drugs (sDMARDs): methotrexate, sulfasalazine, and leflunomide (according to Anatomical Therapeutic Chemical
(ATC) codes in the prescribed drugs register). Any pharmacological treatment: non-steroidal anti-inflammatory drugs (NSAIDs), oral corticosteroids, or
sDMARDs (according to ATC codes in the prescribed drugs register), or tumor necrosis factor inhibitors (TNFi) (according to the Anti-Rheumatic Therapy in
Sweden Register (ARTIS)). IBD: inflammatory bowel disease (according to International Classification of Disease (ICD) codes in the National Patient Register (NPR)).
Peripheral arthritis: psoriatic arthritis, reactive arthritis, polyarthritis, or any type of arthritis (according to ICD codes in the NPR). †At least one dispensed
prescription during 2009 according to the Swedish prescribed drugs register or listed in ARTIS as receiving TNF-α medication during 2009. ††At least one
diagnosis registered in the NPR between 1967 and 2009. †††Adjusted for age and a registered diagnosis of anterior uveitis, psoriasis, IBD, or peripheral
arthritis. SD, standard deviation.
Figure 2 The point prevalence of clinically diagnosed ankylosing
spondylitis (AS) in Sweden on 31 December 2009 among those aged 16 to
64 years according to the base case and strict case definitions, and the
prevalence of clinically diagnosed AS in 2009 for subgroups stratified
according to pharmacological treatment and disease-related clinical
manifestations. Peripheral arthritis defined as psoriatic arthritis, reactive
arthritis, polyarthritis, or any type of arthritis. BC, base case; IBD, inflammatory
bowel disease; NSAID, non-steroidal anti-inflammatory drug; sDMARD,
synthetic disease modifying anti-rheumatic drug; TNF, tumor necrosis factor.
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was 0.24% (95% CI, 0.23 to 0.25%), whereas that in the
Southern Region was 0.16% (95% CI, 0.15 to 0.16%);
however, there was no clear north–south gradient with
regard to prevalence of AS across the rest of the country
(Figure 4).
Level of formal education
The age-/sex-standardized prevalence of clinically diag-
nosed AS was lowest in the population group with >12
years of formal education (0.20%; 95% CI, 0.19 to 0.21%). A
higher prevalence was observed in those with a lower level
of education: ≤9 years (0.24%; 95% CI, 0.22 to 0.25%) or 10
to 12 years (0.24%; 95% CI, 0.23 to 0.24%) of schooling, as
shown in Additional file 5: Figure S3. A lower prevalence of
AS in the population with the highest level of education
was still observed after stratification according to age in
2009 (Figure 5).
Discussion
This nationwide, register-based study revealed that the
point prevalence of clinically diagnosed AS in Sweden in
2009 was 0.18%. The prevalence was lower in those with
Figure 3 The age- and sex-stratified point prevalence of clinically diagnosed ankylosing spondylitis (AS) in Sweden on 31 December 2009, according
to the base case definition.
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the north. Furthermore, the prevalence was higher in men
than women. In addition, the frequency of anterior uveitis
and treatment with TNFi was higher in men than in
women. On the other hand, women had more registered
diagnoses related to peripheral arthritis and psoriasis, and
were more frequently treated with oral corticosteroids.
Estimates of AS prevalence vary considerably. Differ-
ences in study design and population genetics are the
most likely explanations; however, geographical, environ-
mental, and socio-economic factors may also play a role.
In northern Norway, the prevalence of AS is reported to
be 0.21% [13], which is very similar to our own estimates
for northern Sweden. A population survey from Finland
[12], which examined a representative sample of theFigure 4 The point prevalence of clinically diagnosed ankylosing spondylit
definition, among those aged 16 to 64 years in each healthcare region (crupopulation aged ≥30 years (The Mini-Finland Health
Survey) reported a prevalence of 0.15%. Finally, a re-
gional register-based study from southern Sweden [15]
estimated the prevalence of AS in those ≥15 years old to
be 0.12%, which is also consistent with the results we
obtained for the southern region of Sweden when using
the same age restriction and case definition criteria
(data not shown).
According to the results presented herein, sex appears
to play a role in AS prevalence. First, the prevalence of
AS was higher in men than women across all age groups;
this was expected given the results of previous studies
[12,15,7]. Furthermore, a registered visit with a diagnosis
of anterior uveitis was more common among men. Men
were also more likely to be prescribed TNFi than women.is (AS) in Sweden on 31 December 2009 according to the base case
de and standardized according to age and sex).
Figure 5 The point prevalence of clinically diagnosed ankylosing spondylitis (AS) in Sweden on 31 December 2009 (according to the base case
definition), among those aged 30 to 64 years, stratified according to the level of formal education and age in 2009.
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psoriasis, and a prescription for oral corticosteroids were
more common among women. These findings support the
presence of sex-related phenotypic differences, which
could affect treatment choices. However, the differences
between the sexes with regard to pharmacological treat-
ment remained significant, even after adjusting for such
phenotypic differences.
We also found geographical and socio-economic differ-
ences in AS prevalence. Previous studies may have lacked
sufficient data or the power to evaluate such differences
[5,7]. The higher prevalence in northern Sweden (identi-
fied herein) and in northern Scandinavia [11,13,14] may
be explained by population genetics; the prevalence of the
AS-related genotype, HLA-B27, is high (24%) in the indi-
genous population (Sami) in these areas [11]. The fre-
quency of HLA-B27 is lower in the non-Sami populations
of northern Scandinavia (10 to 16%) and Finland (12 to
16%); however, it is still considerably higher than that in
southern Europe [19]. Additionally, the present study is
the first to suggest an inverse relationship between AS
prevalence and the level of education. Such a relationship
was also shown previously for RA [20]. It may illustrate
that the (usually) early age of AS onset may affect one’s
ability to pursue education; however, it may also indicate
that socio-economic or environmental factors may play a
role in AS development. The fact that those exclusively
followed in private care are not included in our study may
introduce a selection bias that affects this analysis. Those
with higher educational attainment (indicating higher
socio-economic status) may be more likely to be treated
in private clinics, and therefore are missing from our sam-
ple. However, in Sweden the majority of private healthcare
providers are reimbursed by the counties for providing
services covered by the same regulations and fees thatapply to municipal care facilities, suggesting that the abil-
ity to contact a private rheumatologist is not strongly
dependent on socio-economic status. Future studies could
focus on identifying environmental factors associated with
AS by linking the populations examined in the present
study to other registers containing information regarding
relevant early life exposure.
The present study has several strengths. First, it is the
first nationwide prevalence study on clinically diagnosed
AS. Previous studies were either based on regional or small
national population samples, with limited generalizability.
Second, in contrast to smaller regional studies, we used a
uniform case ascertainment over a large geographical area,
enabling us to demonstrate geographical variations in
disease occurrence, which may reflect differences in gen-
etic, environmental, and socio-economic factors. Third, the
register-based approach (using AS diagnoses made by phy-
sicians) reflects the real disease burden as estimates of AS
occurrence are based on clinical diagnoses, and enables the
assessment of the frequency of AS-related clinical manifes-
tations and pharmacological treatments.
The study also has a number of limitations. First, a
register-based approach does not identify patients not
seeking contact with a healthcare practitioner, since it
only identified clinically diagnosed cases. Second, the NPR
does not cover AS cases that are managed exclusively in a
primary care or private setting. According to a previous
study from southern Sweden, only 3% of AS patients are
being followed exclusively in primary care [25], usually
those with a mild disease course. In another study, the
proportion of AS cases solely seeking private healthcare
was estimated to be 15% [15]. Our own estimates from
the biologics register show that only 4.6% of those re-
ceiving TNFi are treated exclusively privately (data not
shown). Taking these factors into consideration, although
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mild disease or short disease duration may not be in-
cluded in the present study, our underestimation of AS
prevalence should be less than 10%. Finally, the validity of
an AS diagnosis registered in the NPR may be questioned,
as all diagnoses are based on the judgment of each indi-
vidual physician and not on established classification cri-
teria. However, we previously showed that AS diagnoses
according to the strict case definition have high validity,
with a positive-predictive value of 80% for fulfilling the
modified New York criteria, and 89% for fulfilling any of
the commonly used criteria for SpA [23]. These findings
indicate that only a low percentage of patients with clin-
ical non-radiographic axial SpA are incorrectly classified
as AS in the NPR. Based on these findings, misclassifica-
tion of AS diagnosis in the NPR is unlikely to have a sig-
nificant impact on our results. Finally, the present study
specifically addresses the prevalence of clinically diag-
nosed AS and not that for the whole group of axial SpA
(including the non-radiographic stage). The latter is ex-
pected to be higher and thus more studies are necessary
to estimate the total prevalence of axial SpA.
Conclusions
To conclude, this nationwide, register-based prevalence es-
timate of clinically diagnosed AS in Sweden offers a unique
opportunity to improve our understanding of the real bur-
den that AS places on the healthcare system. We identified
phenotypical and pharmacological treatment differences
between the sexes, and differences in disease prevalence re-
lated to geographical region and socio-economic factors,
suggesting that genetic and (possibly) environmental fac-
tors may be important for the development of AS.
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